Treatment for mental health issues in COVID-19 survivors from intensive care
Detection and Treatment of Long-term Symptoms - Post-covid Syndrome - in Patients Who Have Been Treated in Intensive Care for COVID-19.
This study is trying a new therapy that combines two types of counseling to see if it helps COVID-19 survivors who spent time in intensive care feel better mentally after a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Skane Academic / other |
| Locations | 2 sites (Malmö and 1 other locations) |
| Trial ID | NCT05119608 on ClinicalTrials.gov |
What this trial studies
This pilot randomized controlled trial aims to identify and address mental health problems in survivors of critical COVID-19 infection 12 months after ICU care. Participants will be randomized into two groups: one receiving an intervention combining Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT), and the other receiving standard treatment. The study will assess feasibility measures such as consent, adherence, and satisfaction, while also evaluating the effects on mental health symptoms. The goal is to better understand the mental health challenges faced by these patients and to explore effective treatment options.
Who should consider this trial
Good fit: Ideal candidates are COVID-19 survivors who have screened positive for clinical anxiety or depression 12 months after ICU treatment.
Not a fit: Patients who are acutely suicidal, psychotic, or have severe cognitive or language difficulties may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide effective therapeutic interventions for mental health issues in COVID-19 survivors, improving their quality of life.
How similar studies have performed: While this approach is relatively novel, other studies have explored mental health interventions for COVID-19 survivors, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * COVID-19 survivors who screen positive for clinical anxiety or depression, defined as reaching a score of ≥ 8 on either the anxiety or depression sub-scales within the questionnaire HADS at the standard 12-months follow-up Exclusion Criteria: * Conditions in which patients are acutely suicidal, psychotic, suffering from a mental disorder requiring in-patient psychiatric treatment, opposed to receiving a psycho-therapeutic intervention, or with cognitive problems or language difficulties which are judged to be too extensive for the informed consent procedure and for a psycho-therapeutic intervention
Where this trial is running
Malmö and 1 other locations
- Psychiatry Skåne, Malmö-Trelleborg deparment of psychiatry — Malmö, Sweden (Recruiting)
- Södersjukhuset AB, Region Stockholm — Stockholm, Sweden (Recruiting)
Study contacts
- Study coordinator: Anders Håkansson, PhD
- Email: anders_c.hakansson@med.lu.se
- Phone: +46 46 175596
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.